Current State of Immunotherapy for Lung Cancer: Focusing on Real-World Evidence
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Thoracic Oncology".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 57
Special Issue Editor
2. Department of Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany
Interests: immunotherapy; radiation; lung cancer; combined treatment; real-world data; peripheral biomarkers of immune response
Special Issue Information
Dear Colleagues,
Immunotherapy or the use of immune-checkpoint inhibitors (ICIs) as clinical routine in the treatment of lung cancer has drastically improved patient prognosis. This strong positive survival effect was documented in squamous and non-squamous histology as well as all stages of cancer disease.
The global implementation of ICIs in clinical practice is fast advancing across the world; real-world data and experiences are very intensively produced and will need a substantial analysis and discussion to generate more effective study/treatment concepts in the future. Especially in the field of combined treatment of ICI with chemotherapy, radiation and tumor treating fields (TTFs) in the first or salvage settings, real-world data collection and interpretation are very important.
This Special Issue of Current Oncology will focus on clinical studies and reports describing the efficacy and safety of ICIs in real-life clinical practice. Reports describing the implementation of combined treatment modalities, long-term follow-up results, abscopal effects and immunological phenomena are invited. Studies describing peripheral (blood) biomarkers and imaging signatures of anti-tumor immune response in the real-life setting are of strong interest. In this Special Issue of Current Oncology, we welcome the submission of original research as well as review articles. Also, protocols of ongoing or planned clinical trials, and summaries of interdisciplinary meetings and boards will be considered for publication.
Dr. Farkhad Manapov
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- immunotherapy
- immune-checkpoint inhibition
- radiotherapy
- chemotherapy
- tumor-treating fields
- combined treatment
- real-world evidence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
